All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7502 was presented by William Wierda, The University of Texas MD Anderson Cancer Center, Texas, on the phase II CAPTIVATE study (NCT02910583).
The study assessed the use of ibrutinib plus venetoclax as first-line treatment in chronic lymphocytic leukemia (CLL). A total of 164 patients with treatment-naïve CLL were included in the trial. They were treated with 420mg ibrutinib once daily for 3 cycles and then intravenous venetoclax up to 400mg once daily for 12 cycles. If minimal residual disease (MRD) was confirmed detectable then patients were randomized to receive either placebo or ibrutinib. If MRD was undetectable, not confirmed then patients were randomized to receive either ibrutinib or ibrutinib plus venetoclax (I+V).
Dr Wierda concluded that “these early results show a highly active and safe treatment with 12 cycles of combined treatment with ibrutinib and venetoclax.” See below for an interview with Dr Wierda discussing the study results.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox